Safety and efficacy of co‐administered BCMA and CD19 CAR‐T have been demonstrated in late‐relapsed MM and in high‐risk newly diagnosed (NDMM) post‐ASCT.37, 38. This evidence concerns the gene CD19 and Miyoshi myopathy.